Skip to content
36
Societies
SSMO
Categories
Session

Oral presentation Clinical solid tumor oncology

- , Kairo 1-2

Schedule Slot

Oral presentation Clinical solid tumor oncology

36
Societies
SSMO
Categories
Session

Oral presentation Clinical solid tumor oncology

- , Kairo 1-2
Chair:
Christian Britschgi (Cantonal Hospital Winterthur)
Mascha Binder (Unispital Basel)

  1. Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma: final analysis of the single arm phase II trial SAKK 06/17

    Presentation time:
    10 min
    Discussion time:
    4 min

    Speaker: Cathomas (Cantonal Hospital Graubünden)

  2. Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer: interim analysis of SAKK 06/19 study

    Presentation time:
    10 min
    Discussion time:
    4 min

    Speaker: Cathomas (Cantonal Hospital Graubünden)

  3. Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001–2020): A Meta-Analysis of Pivotal Randomized Controlled Trials

    Presentation time:
    10 min
    Discussion time:
    4 min

    Speaker: Rahimzadeh (University of Zurich)

  4. Co-Alterations Associated with Resistance to EGFR-Inhibitors in EGFR+ NSCLC: Insights from the Precision Oncology Program in Two International Real-World Cohorts

    Presentation time:
    10 min
    Discussion time:
    4 min

    Speaker: Boos (University Hospital Zurich)

  5. Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

    Presentation time:
    10 min
    Discussion time:
    4 min

    Speaker: Schultheiss (University Hospital Basel)

  6. Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy (SAKK 16/14)

    Presentation time:
    10 min
    Discussion time:
    4 min

    Speaker: Da Silva (University of Basel)